Abstract Colorectal cancer (CRC) is a multistep process
based on the accumulation of somatic mutations in genes such
as APC and KRAS. Data on the presence of mutations in
KRAS gene in CRC and its relationship with clinicopathological
parameters and expression of genes involved in tumor
progression are scarce. We unbiasedly examined the KRAS
status in samples from 99 patients and its correlation with
clinicopathological parameters such as age, sex, tumor location,
lymph node metastasis, tumor stage, tumor grade, and
vascular invasion. Consistent with reports of other researchers,
38.4 % of our samples harbored KRAS mutation
in their genomes with preferential mutation in codon 12
(89.4 %). Nevertheless, unlike previous reports, we were not
able to correlate KRAS status with clinicopathological parameters
(P > 0.05) except for vascular invasion. Patients with
KRAS mutation have more vascular invasion compared with
patient having wild-type KRAS. Next, we investigated the
expression of two tumor suppressor genes, factor-inhibiting
hypoxia-inducible factor 1 (FIH-1) and suppressor of cytokine
signaling (SOCS3), in both KRAS mutant and wild-type
groups and looked for any correlation between their expression
and clinicopathological parameters. Although the expression
of both genes was not regular, none of the clinicopathological
parameters were associated with the expressions of
FIH-1 and SOCS3 at mRNA level (P>0.05). However, decline
in FIH-1 expression at protein level in KRAS mutant
group was correlated with stage IV and grade 2 of tumor
(P≤ 0.05). Our results demonstrated that there is no or low
correlation between KRAS status, FIH-1, and SOCS3 expression
with epidemiologic and clinicpathological characteristics
in CRC